Open access
Open access
Powered by Google Translator Translator

[Press Release – not published yet]: RCT: Sanofi-GSK report its vaccine targeted against ancestral and Beta strains had an overall efficacy of 72% against the Omicron variant.

27 Jun, 2022 | 11:52h | UTC

Press Release: Sanofi-GSK first to report a successful efficacy study against Omicron with COVID-19 Beta-containing vaccine – Sanofi

Commentaries: Bivalent COVID Vax Gets Phase III Win Against Omicron, Companies Say — Sanofi, GSK boast of 72% efficacy against Omicron variant – MedPage Today (free registration required)

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.